Loading patent…
AssigneeThe Regents of the University of California
InventorsNancy E. Lane, Ruiwu Liu, Wei Yao, Kit S. Lam
Estimating the term…
The present invention provides methods of treating a subject having a primary inflammatory disease or disorder comprising administering to the subject a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug, wherein the composition comprising the LLP2A-bisphosphonate conjugate enhances the delivery of mesenchymal stem cells to a site of inflammation. Methods of enhancing an anti-inflammatory or immunomodulatory property of mesenchymal stem cells, comprising administering to a subject in need thereof the mesenchymal stem cells and a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug, are also provided.
A method of reducing or slowing peri-articular bone loss associated with rheumatoid arthritis in a subject, the method comprising administering to the subject a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug.
A method of reducing or slowing trabecular bone loss associated with rheumatoid arthritis in a subject, the method comprising administering to the subject a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug.
Dependencies are inferred from the claim text.